Dimension Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Essay

Dimension published "At The Limit" letter (July 2026), the firm's annual letter to limited partners covering firm strategy and market perspective at the intersection of science and compute.

Dimension

dimensioncap.com

Added recently

Dimension | Activity | F4

Investment

Led Lanyon AI's $11M Seed round. Lanyon AI is a neurosymbolic AI platform for high-precision scientific and technical computing applications.

Lanyon AI

Lanyon AI Dimension

caplight.comAUG 17, 2026

prnewswire.com

AUG 17, 2026

New Fund

Dimension announced Dimension III, an $800M fund — 60% larger than its $500M Fund II raised 18 months earlier. The firm now manages $1.65B in assets and has backed 35 companies.

Dimension III

Dimension

techcrunch.comJUL 21, 2026

JUL 21, 2026

Investment

Dimension participated in a $787M Series C for AI-powered cancer and immune drugmaker Earendil Labs.

Earendil Labs

Earendil Labs Dimension

biopharmadive.comJUL 2026

JUL 2026

Milestone

Dimension-backed anti-aging startup NewLimit, co-founded by Coinbase CEO Brian Armstrong, completed a Series C at a $3.1B valuation in July 2026. Dimension led the Series A in January 2025.

NewLimit

NewLimit Dimension

techcrunch.comJUL 2026

JUL 2026

Milestone

Dimension-backed Chai Discovery raised $400M at a $3.8B valuation. Dimension co-led the $30M seed investment in 2024.

Chai Discovery

Chai Discovery Dimension

techcrunch.comJUL 2026

JUL 2026

Essay

Dimension published its annual fund letter "At The Limit" (July 2026) covering firm strategy at the intersection of science and compute.

Dimension

Dimension Dimension

dimensioncap.comJUL 2026

JUL 2026

Investment

Led Chai Discovery's Series C round (Jul 2026), following prior participation in their $130M Series B at $1.3B valuation.

Chai Discovery

Chai Discovery Dimension

caplight.comJUL 2026

businesswire.com

JUL 2026

Exit

Portfolio company Odyssey Therapeutics began trading on Nasdaq under ODTX after pricing an upsized IPO.

Odyssey Therapeutics

Odyssey Therapeutics Dimension

nasdaq.comMAY 8, 2026

investors.odysseytx.com

MAY 8, 2026

Milestone

Dimension portfolio company Odyssey Therapeutics completed a $279M IPO in May 2026. Dimension spearheaded a crossover round and helped anchor the IPO.

Odyssey Therapeutics

Odyssey Therapeutics Dimension

biopharmadive.comMAY 2026

MAY 2026

Essay

Simon Barnett, Partner at Dimension, co-authored an essay "Don't Fall in Love with Your Molecule" on the Dimension Research blog, discussing drug discovery decision-making.

"Don't Fall in Love with Your Molecule" by Simon Barnett

Dimension

research.dimensioncap.comAPR 2026

APR 2026

Exit

Dimension portfolio company Coefficient Bio (Coefficient Labs), a stealth drug discovery platform, was acquired by AI giant Anthropic for $400M in April 2026. Dimension received shares in Anthropic as part of the deal.

Coefficient Bio

Coefficient BioDimension

biopharmadive.comAPR 2026

APR 2026

Investment

Participated in Earendil Labs' $787M financing round. Earendil Labs is an AI-powered biologics discovery and development platform.

Earendil Labs

Earendil Labs Dimension

prnewswire.comMAR 20, 2026

MAR 20, 2026

New Fund

Dimension began raising Fund III, targeting approximately $700M to invest in companies melding AI and science.

Dimension

Dimension Dimension

statnews.comMAR 17, 2026

MAR 17, 2026

Page 1 of 2